80%Confidence
0Views
FDASource
2026-04-21Date
Summary
Teva Pharmaceuticals faces a recall for a clonidine patch due to CGMP deviations involving unapproved raw materials. This highlights supply chain and quality assurance vulnerabilities that could affect its generic drug portfolio.
Actionable: Review Teva's compliance track record and consider the potential for broader regulatory actions impacting its manufacturing sites.
AI Confidence: 80%
Data Points
firmTeva Pharmaceuticals USA, Inc
classificationClass II
statusOngoing
distributionWithin U.S
productClonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Covers, Rx only, Manufactured by: Actavis Laboratories
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now